8-K: Bio-Path Holdings Increases At-The-Market Offering After Selling $2 Million in Shares

Bio-Path Holdings has terminated its previous at-the-market offering and initiated a new offering to sell up to an additional $1.1 million in common stock.

Summary

• Bio-Path Holdings previously sold 436,511 shares of common stock for gross proceeds of approximately $2.0 million through an at-the-market offering.
• The company has terminated the previous offering effective April 19, 2024.
• Bio-Path Holdings has increased the amount available for sale under its at-the-market offering agreement by up to an additional $1,107,871.
• The new offering will be made under the company's existing shelf registration statement and a new prospectus supplement filed on April 19, 2024.
• The company is not obligated to sell any shares under the agreement.
• H.C. Wainwright & Co., LLC will act as the sales agent and will use commercially reasonable efforts to sell shares based on the company's instructions.
• The net proceeds from this offering are intended for working capital and general corporate purposes.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the company is raising additional capital, which is necessary for operations, but it also dilutes existing shareholders. The offering is expected and not a surprise.

Positives

• The company successfully raised $2.0 million through the previous at-the-market offering.
• The company has secured an additional avenue for raising capital through the new offering.
• The company has flexibility in the timing and amount of shares sold under the agreement.

Negatives

• The company is diluting existing shareholders by issuing more shares.
• There is no guarantee that the company will sell all of the shares offered.
• The company's stock price may be negatively impacted by the increased supply of shares.

Risks

• The company may not be able to sell all of the shares offered under the agreement.
• The company's stock price may be negatively impacted by the increased supply of shares.
• The company's reliance on at-the-market offerings may indicate a lack of other funding options.

Future Outlook

The company intends to use the net proceeds from the offering for working capital and general corporate purposes, but there is no guarantee that all shares will be sold.

Industry Context

At-the-market offerings are a common method for small-cap biotech companies to raise capital, especially when other funding options are limited. This is a common practice in the biotech industry.

Comparison to Industry Standards

• Many small-cap biotech companies use at-the-market offerings to raise capital, as traditional financing can be difficult to secure.
• The size of this offering is relatively small compared to some other biotech companies, which may raise tens or hundreds of millions of dollars in a single offering.
• The use of H.C. Wainwright as a sales agent is common in the biotech sector, as they have experience in this type of offering.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• The company will have additional working capital to fund operations.
• The company's stock price may be negatively impacted by the increased supply of shares.

Next Steps

• The company will continue to offer and sell shares of common stock through H.C. Wainwright & Co., LLC.
• The company will use the net proceeds for working capital and general corporate purposes.

Key Dates

Keywords

at-the-market offering, common stock, capital raise, H.C. Wainwright, securities, Bio-Path Holdings, equity financing